Pancreatic Adenocarcinoma
Conditions
Interventions
Study group:SOXIRI chemotherapy
Sponsors
Fudan University Affiliated Huadong Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75, men or women; 2. A histologically or cytologically proven diagnosis of pancreatic adenocarcinoma; 3. An eastern Cooperative Oncology Group (ECOG) performance status of 1 or less; 4. Without the history of chemotherapy or radiotherapy in six months; 5. Without severe hematological, cardiopulmonary, and immune disorders; 6. Absolute neutrophil count =1.5*10^9 /L, platelet count =100*10^9/L, hemoglobin =8g/L 7. Serum transaminases = 2.5*the upper normal limit (ULN), total bilirubin =1.5*ULN (in cases of biliary stent, total bilirubin =3.0*ULN) , alkaline phosphatase =2.5*ULN, serum creatinine =1.5*ULN; 8. Prothrombin time and International Normalized Ratio=1.5*ULN.
Exclusion criteria
Exclusion criteria: 1. The patient has been allergic to the medicines; 2. The patient has took part in other clinical trial at the same time; 3. The patient has received blood infusions or blood products within 15 days; 4. The patient has undergone major operation within 4 weeks; 5. The patient has gut dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;One year survival; | — |
Countries
China
Contacts
Public ContactChongyi Jiang
Fudan University Affiliated Huadong Hospital
Outcome results
None listed